Lung cancer is one of the leading causes of cancer-related death in the United States. For this reason, researchers have focused on developing new treatments to manage symptoms and improve outcomes for patients. The past year was a breakthrough year for the treatment of lung cancer, with numerous drugs entering the market, many of which replaced older therapies as the new standard of care. Some of these new drugs also represent new trends in cancer care, such as the rise of immunotherapies. This slideshow highlights the drugs approved by the US Food and Drug Administration in the last year, as well as the results that led to their approval.